Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker.
作者信息
Foley John F, Stuve Olaf
机构信息
From the Rocky Mountain Multiple Sclerosis Clinic (J.F.F.), Salt Lake City, UT; Department of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center at Dallas; and Neurology Section (O.S.), VA North Texas Health Care System, Medical Service, Dallas.
出版信息
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 10;7(3). doi: 10.1212/NXI.0000000000000706. Print 2020 May.
Abstract
摘要
相似文献
1
Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker.那他珠单抗药效减退效应：寻找难以捉摸的药效学生物标志物。
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 10;7(3). doi: 10.1212/NXI.0000000000000706. Print 2020 May.
2
The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.那他珠单抗失效效应：那他珠单抗周期结束，MS 症状复发。
Neurology. 2019 Oct 22;93(17):e1579-e1586. doi: 10.1212/WNL.0000000000008357. Epub 2019 Sep 24.
3
Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not "mind the gap".那他珠单抗药效减退症状：接受延长给药间隔治疗的多发性硬化症患者可能不会“在意间隔”。
Neurology. 2019 Oct 22;93(17):735-736. doi: 10.1212/WNL.0000000000008358. Epub 2019 Sep 24.
4
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.八周内从那他珠单抗转换为芬戈莫德——探寻最佳转换方案的免疫学、临床及影像学数据
Clin Immunol. 2017 Mar;176:87-93. doi: 10.1016/j.clim.2017.01.001. Epub 2017 Jan 17.
5
Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.造血动员：多发性硬化症中对那他珠单抗反应的潜在生物标志物。
Neurology. 2015 Apr 7;84(14):1473-82. doi: 10.1212/WNL.0000000000001454. Epub 2015 Mar 11.
6
Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.那他珠单抗治疗进展型多发性硬化症：一项开放标签、2A期概念验证试验的结果
Neurology. 2014 Apr 29;82(17):1499-507. doi: 10.1212/WNL.0000000000000361. Epub 2014 Mar 28.
7
Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.那他珠单抗对复发缓解型多发性硬化症氧化损伤生物标志物的影响。
Pharmacol Rep. 2013;65(3):624-31. doi: 10.1016/s1734-1140(13)71039-9.
8
CD49d expression as a promising biomarker to monitor natalizumab efficacy.CD49d 表达作为监测那他珠单抗疗效的有前途的生物标志物。
J Neurol Sci. 2012 Mar 15;314(1-2):138-42. doi: 10.1016/j.jns.2011.10.005. Epub 2011 Nov 1.
9
Cardiovascular profile improvement during Natalizumab treatment.那他珠单抗治疗期间心血管特征的改善。
Metab Brain Dis. 2018 Jun;33(3):981-986. doi: 10.1007/s11011-017-0169-z. Epub 2017 Dec 18.
10
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.多发性硬化症患者中断那他珠单抗治疗期间疾病活动的复发。
Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.
本文引用的文献
1
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.在那他珠单抗给药间隔结束时出现的药物失效与低受体占有率有关。
Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(3). doi: 10.1212/NXI.0000000000000678. Print 2020 May 4.
2
The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.那他珠单抗失效效应：那他珠单抗周期结束，MS 症状复发。
Neurology. 2019 Oct 22;93(17):e1579-e1586. doi: 10.1212/WNL.0000000000008357. Epub 2019 Sep 24.
3
Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.评估纳武单抗药代动力学和药效学与标准和延长间隔给药。
Mult Scler Relat Disord. 2019 Jun;31:65-71. doi: 10.1016/j.msard.2019.03.017. Epub 2019 Mar 26.
4
Natalizumab: Perspectives from the Bench to Bedside.那他珠单抗：从基础到临床的观点。
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a029066. doi: 10.1101/cshperspect.a029066.
5
Immune surveillance in multiple sclerosis patients treated with natalizumab.接受那他珠单抗治疗的多发性硬化症患者的免疫监视
Ann Neurol. 2006 May;59(5):743-7. doi: 10.1002/ana.20858.
6
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction.如显微操作和单细胞聚合酶链反应所示，CD8(+) T细胞的克隆性扩增在活动性多发性硬化病变的T细胞浸润中占主导地位。
J Exp Med. 2000 Aug 7;192(3):393-404. doi: 10.1084/jem.192.3.393.
7
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.多发性硬化症中的髓鞘自身反应性：多发性硬化症患者和健康供体的T淋巴细胞在HLA - DR2产物背景下对髓鞘碱性蛋白的识别。
Proc Natl Acad Sci U S A. 1990 Oct;87(20):7968-72. doi: 10.1073/pnas.87.20.7968.
8
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis.多发性硬化症中免疫显性髓鞘碱性蛋白表位的T细胞识别
Nature. 1990 Jul 12;346(6280):183-7. doi: 10.1038/346183a0.
Zotero 插件